DK0462187T3 - Farmaceutisk præparat, som kan anvendes til forebyggelse eller behandling af papillomvirusinducerede tumorer - Google Patents
Farmaceutisk præparat, som kan anvendes til forebyggelse eller behandling af papillomvirusinducerede tumorerInfo
- Publication number
- DK0462187T3 DK0462187T3 DK90904636.9T DK90904636T DK0462187T3 DK 0462187 T3 DK0462187 T3 DK 0462187T3 DK 90904636 T DK90904636 T DK 90904636T DK 0462187 T3 DK0462187 T3 DK 0462187T3
- Authority
- DK
- Denmark
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- papilloma virus
- induced tumors
- Prior art date
Links
- 241001631646 Papillomaviridae Species 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 241000341655 Human papillomavirus type 16 Species 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8902897A FR2643817B1 (fr) | 1989-03-06 | 1989-03-06 | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0462187T3 true DK0462187T3 (da) | 1993-10-18 |
Family
ID=9379397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK90904636.9T DK0462187T3 (da) | 1989-03-06 | 1990-03-06 | Farmaceutisk præparat, som kan anvendes til forebyggelse eller behandling af papillomvirusinducerede tumorer |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0462187B1 (da) |
| JP (1) | JP2926270B2 (da) |
| AT (1) | ATE91630T1 (da) |
| CA (1) | CA2050304C (da) |
| DE (1) | DE69002325T2 (da) |
| DK (1) | DK0462187T3 (da) |
| ES (1) | ES2058898T3 (da) |
| FR (1) | FR2643817B1 (da) |
| WO (1) | WO1990010459A1 (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| CA2158977A1 (en) | 1994-05-09 | 1995-11-10 | James G. Respess | Retroviral vectors having a reduced recombination rate |
| US6013517A (en) * | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
| AUPN443995A0 (en) * | 1995-07-27 | 1995-08-17 | Csl Limited | Papillomavirus polyprotein |
| US7118754B1 (en) | 1996-07-30 | 2006-10-10 | Transgene S.A. | Pharmaceutical composition for treating papillomavirus tumors and infection |
| FR2751879B1 (fr) * | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
| US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
| US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
| US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
| US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
| EP1425039A4 (en) | 2001-03-23 | 2005-02-02 | Us Gov Health & Human Serv | PEPTIDES THAT GIVE AN IMMUNE REACTION WITH THE HUMAN PAPILLOMA VIRUS |
| AU2004263274B2 (en) | 2003-07-21 | 2009-11-05 | Transgene S.A. | Novel multifunctional cytokines |
| AU2003290460A1 (en) * | 2003-12-24 | 2005-07-14 | Leiden University Medical Center | Synthetic protein as tumor-specific vaccine |
| PE20081723A1 (es) | 2007-01-30 | 2008-12-14 | Transgene Sa | Vacuna contra el papilomavirus |
| EP2382474B1 (en) | 2009-01-20 | 2015-03-04 | Transgene SA | Soluble icam-1 as biomarker for prediction of therapeutic response |
| WO2010108908A1 (en) | 2009-03-24 | 2010-09-30 | Transgene Sa | Biomarker for monitoring patients |
| NZ594896A (en) | 2009-04-17 | 2013-07-26 | Transgene Sa | Biomarker for monitoring patients |
| US8445270B2 (en) | 2009-05-12 | 2013-05-21 | Transgene S.A. | Immortalized avian cell lines and use thereof |
| RU2552292C2 (ru) | 2009-07-10 | 2015-06-10 | Трансжене Са | Биомаркер для отбора пациентов и связанные с ним способы |
| IN2012DN01577A (da) | 2009-07-21 | 2015-06-05 | Transgene Sa | |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| WO2014066443A1 (en) | 2012-10-23 | 2014-05-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| JP6655618B2 (ja) | 2014-12-01 | 2020-02-26 | トランジェーヌＴｒａｎｓｇｅｎｅ | 安定な液体ワクシニアウイルス処方物 |
| JP2020519666A (ja) | 2017-05-15 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 安定性のウイルス含有組成物 |
| CA3062549A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| EP3847246A1 (en) | 2018-09-06 | 2021-07-14 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| AU2021233167A1 (en) | 2020-03-12 | 2022-09-22 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
-
1989
- 1989-03-06 FR FR8902897A patent/FR2643817B1/fr not_active Expired - Lifetime
-
1990
- 1990-03-06 WO PCT/FR1990/000151 patent/WO1990010459A1/fr active IP Right Grant
- 1990-03-06 EP EP90904636A patent/EP0462187B1/fr not_active Expired - Lifetime
- 1990-03-06 DE DE90904636T patent/DE69002325T2/de not_active Expired - Lifetime
- 1990-03-06 ES ES90904636T patent/ES2058898T3/es not_active Expired - Lifetime
- 1990-03-06 CA CA002050304A patent/CA2050304C/fr not_active Expired - Lifetime
- 1990-03-06 JP JP2504672A patent/JP2926270B2/ja not_active Expired - Lifetime
- 1990-03-06 DK DK90904636.9T patent/DK0462187T3/da active
- 1990-03-06 AT AT90904636T patent/ATE91630T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2643817B1 (fr) | 1993-12-17 |
| CA2050304C (fr) | 2002-01-22 |
| DE69002325T2 (de) | 1993-12-02 |
| ES2058898T3 (es) | 1994-11-01 |
| WO1990010459A1 (fr) | 1990-09-20 |
| JPH05503282A (ja) | 1993-06-03 |
| JP2926270B2 (ja) | 1999-07-28 |
| ATE91630T1 (de) | 1993-08-15 |
| EP0462187A1 (fr) | 1991-12-27 |
| CA2050304A1 (fr) | 1990-09-07 |
| EP0462187B1 (fr) | 1993-07-21 |
| DE69002325D1 (de) | 1993-08-26 |
| FR2643817A1 (fr) | 1990-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0462187T3 (da) | Farmaceutisk præparat, som kan anvendes til forebyggelse eller behandling af papillomvirusinducerede tumorer | |
| ATE97164T1 (de) | Rekombinantes vaccinia-virus mva. | |
| DE69535018D1 (de) | Papillomavirus vakzine | |
| DE69435332D1 (de) | Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen | |
| LU91387I2 (fr) | CERVARIX - La combinaison des particules similaires au virus HPV16 et HPV18 | |
| ES2191663T3 (es) | Virus recombinante de la viruela porcina. | |
| MY139031A (en) | Vaccine composition comprising virus-like particles of human papillomavirus | |
| DK1090033T3 (da) | Partikler af HCV-kappeproteiner: Anvendelse til vaccination | |
| PT97316A (pt) | Sequencias de dna,construcoes de dna e metodo para a sua aplicacao no tratamento de doencas celulares proliferativas | |
| ATE141946T1 (de) | Hiv-2-virusvarianten | |
| KR970701062A (ko) | 폭스비루스(poxvirus) 성분의 조합에 기초한 파라뮤니티(paramunity) 유발인자(inducer), 그의 제조방법 및 그의 약제에의 이용 | |
| MY150893A (en) | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines | |
| WO2001021807A8 (en) | Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof | |
| ATE313641T1 (de) | Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter | |
| ATE341339T1 (de) | Zusammensetzungen von rekombinanten papillomavirus vakzinen | |
| WO2002083896A3 (en) | Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same | |
| HUP9904201A1 (hu) | Génterápiában használható, egy exogén nukleinsavat genomjában beépítve tartalmazó rekombináns vírus és egy nem virális és nem plazmid transzfektáló szer kombinációját tartalmazó transzfektáló készítmény |